Published online Apr 18, 2015. doi: 10.4254/wjh.v7.i5.725
Peer-review started: November 29, 2014
First decision: December 12, 2014
Revised: December 22, 2014
Accepted: January 18, 2015
Article in press: January 20, 2015
Published online: April 18, 2015
Core tip: Twenty-five years after the discovery of hepatitis C virus (HCV) as the major cause of non-A, non-B post-transfusion hepatitis, we have entered a new era in HCV treatment that indicates the prospect of eradication of this important human pathogen. In this article, we will discuss the promising opportunities ahead and key future challenges in the era of new hepatitis C treatments, i.e., barriers in identifying HCV infected individuals, access to new HCV drugs, emergence of drug resistance, and the current status of HCV vaccine development.